CD44 and prostate cancer: According to Turkekuk K. and co-workers (2023), nanoliposome—quercetin nanoparticles—showed promising effects on CD44+ cancer stem cells isolated from PC-3 (human androgen resistant) and LNCaP (androgen-sensitive) prostate cancer cell lines, through the inhibition of Wnt/β-catenin signaling pathways, the down-regulation of N-cadherin, p-ERK, and fibronectin [129].